Two More Patients Dosed in Solid Trial of DMD Gene Therapy SGT-001

Two More Patients Dosed in Solid Trial of DMD Gene Therapy SGT-001

294432

Two More Patients Dosed in Solid Trial of DMD Gene Therapy SGT-001

Two more participants have been dosed in the IGNITE DMD clinical trial, bringing to eight the total number of Duchenne muscular dystrophy (DMD) patients thus far given Solid Biosciences‘ investigational gene therapy SGT-001. The U.S. trial is testing SGT-001’s safety and efficacy in boys with DMD ages 4 to 17. Solid noted that the eighth patient experienced a serious adverse event (SAE), but is recovering. “We are pleased to have progressed with dosing patients in…

You must be logged in to read/download the full post.